Our Technology Platform:
We have developed methods to tether bioactive molecules (e.g., growth factors, antibodies, receptor ligands, etc.) to single-chain, soluble biopolymers such as hyaluronic acid. By coupling one or more bioactive molecules to the polymers at defined ratios, we can formulate drugs with the following advantages over the untethered molecules:
- enhanced efficacy after local administration
- less frequent administration (more convenient and improved safety)
- enable the use of best-in-class drugs for new clinical indications
Using this technology, we have initiated the development of three protein-based therapies that we expect will dramatically improve the current treatment strategies for a variety of diseases.